NeuroRx CEO and chairman Jonathan Javitt said: “We at NeuroRx are enormously appreciative of the FDA’s commitment to accelerating the development of any potential treatment for Covid-19.
We hope to live up to the trust that has been placed in us by bringing a life-saving treatment to patients.” The Phase II / III trials of RLF-100 are being performed at multiple medical centres, including the University of Miami, Houston Methodist Hospital, University of California-Irvine, NYU Langone Medical Center, and Rambam Healthcare Campus in Haifa, Israel.
This trial is meant for patients with critical Covid-19 and respiratory failure. It is expected that the drug candidate can reduce mortality and improve blood oxygenation by protecting alveolar.